Subscribe to Newsletter

May 2018 Issue of The Medicine Maker

Welcome to the May issue. Find out how an edible QR code could help fight fake medicine, and why funding is being offered to develop a universal flu vaccine. And in In My View, Misagh Naderi and Jeremy Drummond argue the case for drug repurposing for rare diseases and the eye, respectively. Our cover feature takes a look at the current state of the biosimilars field – and the myths preventing wider use – with experts from across the industry. NextGen explores a collaboration planning to use machine learning to accelerate drug discovery, and finally, we sit down with Cyrus Krakaria, President of Biotechnology for Lupin Limited.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Login
Forgot your password?
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

 Manufacture Biosimilars

Open Your Mind

| Roisin McGuigan

Why is the pharma industry overly reluctant to accept new ideas?
Manufacture Technology and Equipment

Print it, Eat it

| Roisin McGuigan

Could drug-containing QR codes fight fakes and avoid medication errors?
Discovery & Development Drug Delivery

Wake Up and Smell the Polymer

| Roisin McGuigan

Caffeine isn’t just a catalyst to get you moving in the morning – it can also help create polymers for drug delivery.
Manufacture Vaccines

Go Forth and Find a Flu Vaccine!

| Stephanie Vine

Bill Gates has issued a challenge to help researchers push for a universal flu vaccine.
Manufacture

A Life Too Short

| Stephanie Vine

Researchers celebrate a new breakthrough into progeria, and urge others to help them find a cure.
Manufacture Drug Delivery

Staying on Target

| Roisin McGuigan

What characteristics make a cancer therapy more likely to effectively treat disease?
Business & Regulation Biosimilars

Business in Brief

| Stephanie Vine

The latest business news and views in pharma.
Business & Regulation Business Practice

Get ‘Em While They’re Young

| Stephanie Vine

Pharmacy students take medicine safety lessons to school classrooms.
Manufacture Business Practice

Trials of a Medicine Maker

Gene and Eva discuss the importance of being cautious when choosing a new supplier.
Discovery & Development Technology and Equipment

Old Drugs, New Computational Tools

| Misagh Naderi

Drug repurposing can benefit many areas of drug discovery – particularly rare diseases.
Discovery & Development Drug Delivery

It Doesn’t Have To End In Tears

| Jeremy Drummond

Rare diseases aren’t the only field that can benefit from repurposing – the eye is also often overlooked.
Discovery & Development Biosimilars

I’m a (Biosimilars) Believer!

| Stephanie Vine

Why does the full potential of biosimilars remain untapped? Four experts weigh in.
Manufacture Biosimilars

Who Wants to Put Biosimilars to the Test

WHO is investigating the potential of certain biosimilars in a prequalification pilot program.

Discovery & Development Biosimilars

What Regulators Want

| Bruno Speder

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.
Business & Regulation Biosimilars

A New Supporter

| Stephanie Vine

Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.

Business & Regulation Biosimilars

Land of Opportunity

| Stephanie Vine

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.
Business & Regulation Technology and Equipment

Medicina Ex Machina

| Roisin McGuigan

Artificial intelligence could have a huge impact on drug discovery.
Manufacture Clinical Trials

Recognizing Friend from Foe

| Werner Cautreels

New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.
Business & Regulation Business Practice

Easy as B to D?

The Trump Administration’s plans to move Medicare Part B drugs into the Part D system would mean additional delays and cost barriers for patients.
Manufacture Business Practice

Biosimilar Backer

| Stephanie Vine

Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.
Manufacture Standards & Regulation

Stay Ahead. Smart Risk Management

Collaboration is crucial for supply continuity and control.
Manufacture Technology and Equipment

Industrializing Cell Therapy

| Phil Vanek

We know that cell therapies work; now, we need to learn to manufacture them efficiently on an industrial scale.
Manufacture Bioprocessing - Single Use Systems

Flexibility without compromise

Other issues of 2018